A pharmaceutical composition for killing head and neck cancer cells and use thereof

Abstract

The application relates to the technical field of biological medicine, and provides a pharmaceutical composition for killing head and neck cancer cells and application thereof, which comprises low-deuterium water, selenium-containing extract, extract of cassia seed and extract of honeysuckle. The application constructs a multi-target synergistic anti-tumor system by specifically matching the low-deuterium water as an active carrier with various active extracts, can efficiently inhibit the proliferation of head and neck cancer cells and induce the apoptosis of the head and neck cancer cells, significantly enhances the sensitivity of the head and neck cancer cells to cisplatin, reduces the dosage and side effects of the chemotherapeutic drugs, improves the tumor microenvironment and enhances the immune function of the body, and provides a new scheme of reducing toxicity and increasing efficiency for the clinical treatment of head and neck cancer.

Description

Technical Field

[0001] This application relates to the field of biomedical technology, specifically to a pharmaceutical composition for killing head and neck cancer cells and its application. Background Technology

[0002] Head and neck cancer is a general term for malignant tumors occurring in the head and neck region. Clinical treatment mainly relies on surgery, radiotherapy, and chemotherapy. However, existing radiotherapy and chemotherapy methods generally suffer from significant side effects, easy development of drug resistance, and high recurrence rates. In particular, serious complications such as oral mucositis, decreased immune function, and digestive disorders often occur during treatment, significantly reducing patients' quality of life and treatment adherence. In recent years, although deuterium-rich water, selenium preparations, and natural products such as cassia seed and honeysuckle have shown some potential in anti-tumor research, current technologies mostly involve the application of single components or simple physical mixing. There is a lack of composite preparations based on specific solvent effects and deep synergistic effects of multiple target components, resulting in limited killing efficiency against head and neck cancer cells and difficulty in effectively overcoming the drug resistance and toxicity problems of chemotherapy drugs. Therefore, there is an urgent need to develop a drug composition that can efficiently kill head and neck cancer cells through the synergistic effect of multiple components, while reducing toxic side effects and enhancing chemotherapy sensitivity. Summary of the Invention

[0003] In view of the problems of large toxic side effects, limited efficacy of single-component treatments and easy development of drug resistance in existing head and neck cancer treatments, this application proposes a pharmaceutical composition for killing head and neck cancer cells and its application, which achieves the technical effect of multi-target synergistic killing of tumor cells, reducing toxic side effects and enhancing the sensitivity of chemotherapy drugs.

[0004] To achieve the above objectives, this application adopts the following technical solution:

[0005] A pharmaceutical composition for killing head and neck cancer cells, the pharmaceutical composition comprising deuterated water, a selenium-containing extract, a cassia seed extract, and a honeysuckle extract.

[0006] The above-mentioned scheme constructs a synergistic anti-tumor system of "carrier-enhanced penetration + multi-target intervention" by using deuterium-containing water as an active carrier in a specific combination with selenium-containing extracts, cassia seed extract, and honeysuckle extract. Deuterium-containing water improves the solubility and cellular uptake of active ingredients through its unique hydrogen bond network structure, selenium-containing extracts induce apoptosis in cancer cells, and cassia seed and honeysuckle extracts exert anti-inflammatory and immunomodulatory effects. The four components work synergistically to achieve highly efficient killing of head and neck cancer cells.

[0007] In one embodiment, the pharmaceutical composition comprises the following components in parts by weight: 400-600 parts of the deuterated water; 1-3 parts of the selenium-containing extract; 0.5-2 parts of the cassia seed extract; and 0.5-2 parts of the honeysuckle extract.

[0008] This embodiment defines the preferred ratio range of each component, within which the solvent effect of deuterium water and the pharmacodynamic effects of each active ingredient are optimally balanced, ensuring both the stability of the compound preparation and the full realization of the synergistic effect, and avoiding fluctuations in efficacy caused by an excess or deficiency of a certain component.

[0009] In one embodiment, the pharmaceutical composition comprises the following components in parts by weight: 500 parts of the deuterated water; 2 parts of the selenium-containing extract; 1 part of the cassia seed extract; and 1 part of the honeysuckle extract.

[0010] This implementation method represents the validated optimal ratio. At this ratio, the compound formulation exhibits the lowest half-maximal inhibitory concentration (IC50) against head and neck cancer cells, and the most significant sensitizing effect when used in combination with cisplatin, demonstrating the best synergistic interaction among the components.

[0011] In one embodiment, the deuterium concentration of the low-deuterium water is less than or equal to 120 ppm; the selenium-containing extract is a high-methylselenocysteine ​​selenium-enriched malt extract.

[0012] This implementation method clarifies the activity threshold of low-deuterium water and the specific form of the selenium source. Low-deuterium water with a deuterium concentration ≤120ppm can effectively interfere with the deuteration metabolic reaction in tumor cells and inhibit cell division; compared with inorganic selenium or other organic selenium, high-methylselenocysteine ​​has higher bioavailability and targeted apoptosis-inducing ability, and lower toxicity.

[0013] In one implementation method, the deuterium concentration of the low-deuterium water is less than or equal to 100 ppm. It is prepared by electrolysis to generate low-deuterium hydrogen followed by re-combustion. Alternatively, it can be purchased directly as a byproduct of heavy water production. The high-methylselenocysteine-enriched selenium-containing malt extract is prepared by refluxing high-methylselenocysteine-enriched selenium-containing malt in dimethyl carbonate for 3 hours under argon protection (the weight of the high-methylselenocysteine-enriched selenium-containing malt is 10% of the weight of dimethyl carbonate), followed by vacuum evaporation to dry the solvent, yielding the extract. The high-methylselenocysteine-enriched selenium-containing malt is provided by Sichuan Xichuan Biotechnology Co., Ltd., and its preparation method has been patented (application number: 202610308223.7). The selenium content is not less than 1000 ppm, and the methylselenocysteine ​​content is not less than 800 ppm.

[0014] This implementation method further defines the quality indicators of the core active ingredient. A deuterium concentration of ≤100ppm enhances the biological effects of low-deuterium water; a high content of methylselenocysteine ​​ensures that sufficient active selenium enters cancer cells and is converted into hydrogen selenide, triggering the mitochondrial apoptosis pathway, thereby ensuring batch-to-batch consistency and clinical efficacy of the formulation.

[0015] As one embodiment, the cassia seed extract is obtained by reflux extraction of cassia seed slices with 70% ethanol three times, combining the filtrates, concentrating to a relative density of 1.20 (60℃), and spray drying to obtain powder, with an anthraquinone content ≥15%; the honeysuckle extract is obtained by decocting honeysuckle medicinal material with water twice, combining the decoctions, and purifying by adsorption with macroporous resin, with a chlorogenic acid content ≥20%.

[0016] This implementation method defines the key pharmacodynamic material basis for the synergistic effects of traditional Chinese medicine extracts. Anthraquinone components and chlorogenic acid not only have direct antitumor activity, but also improve the tumor microenvironment through anti-inflammatory and antioxidant mechanisms, assisting selenium compounds and deuterium-rich water in exerting a stronger killing effect.

[0017] In one embodiment, the anthraquinone component in the cassia seed extract has a mass percentage greater than or equal to 15%; the chlorogenic acid in the honeysuckle extract has a mass percentage greater than or equal to 20%; the cassia seed extract is obtained by extracting cassia seeds with an ethanol-water solution; and the honeysuckle extract is obtained by extracting honeysuckle with water.

[0018] This implementation method specifies the minimum content of the active ingredient and the extraction process, ensuring the enrichment of active substances in the extract. The specific extraction solvent system (ethanol-water solution and water) effectively retains the moderately polar antitumor active components while removing ineffective impurities, providing a material guarantee for the synergistic effect of the compound formulation.

[0019] In one embodiment, the dosage form of the pharmaceutical composition is an oral liquid or a lyophilized powder for injection.

[0020] This embodiment provides a formulation suitable for clinical administration. The oral solution facilitates long-term use and adjuvant therapy during radiotherapy and chemotherapy, while the lyophilized powder for injection improves the stability of the active ingredient and is suitable for intravenous administration scenarios requiring precise dosage control.

[0021] In addition, this application also provides the use of the pharmaceutical composition as described above in the preparation of a drug for killing head and neck cancer cells.

[0022] The above applications establish the pharmaceutical use of this drug composition in the treatment of head and neck cancer, providing a legal basis and technical support for its development as an anti-tumor drug or adjuvant therapy.

[0023] In one embodiment, the head and neck cancer cells include nasopharyngeal cancer cells, laryngeal cancer cells, or oral cancer cells; the drug is a chemosensitizer used in combination with cisplatin.

[0024] This implementation method clarifies the specific indications and combination therapy strategies. Experiments have confirmed that the composition has a specific killing effect on head and neck cancer cell lines such as FaDu, and can significantly reduce the IC50 value of cisplatin, indicating that it can be used as a chemotherapy sensitizer to reduce the dosage of cisplatin, thereby reducing the toxic side effects caused by chemotherapy while maintaining or enhancing the therapeutic effect.

[0025] Beneficial effects:

[0026] The pharmaceutical composition provided in this application exhibits an unexpected synergistic effect through the specific combination of deuterium-containing water and various active extracts. Firstly, the deuterium-containing water does not merely act as an inert solvent; rather, by reducing the intracellular D / H ratio and altering the hydrogen bond network structure of water molecules, it directly inhibits tumor cell mitosis and significantly improves the transmembrane transport efficiency and intracellular retention of selenium-containing extracts and active ingredients from traditional Chinese medicine, achieving a dual effect of "carrier-enhanced permeation" and "metabolic intervention." Secondly, high-methylselenocysteine, anthraquinone components from cassia seed, and chlorogenic acid from honeysuckle form a multi-target anti-tumor network in the deuterium-containing water medium, synergistically killing cancer cells from multiple dimensions, including apoptosis induction, anti-inflammatory immune regulation, and oxidative stress regulation. Its anti-cancer effect is significantly superior to that of individual components or ordinary aqueous solvent systems. Finally, this composition can significantly improve the sensitivity of head and neck cancer cells to cisplatin, drastically reducing the half-maximal inhibitory concentration (IC50) of cisplatin, providing a new solution for reducing the toxicity and enhancing the efficacy of chemotherapy in clinical practice, and possessing significant clinical application value. Attached Figure Description

[0027] Figure 1 To determine the half-maximal inhibitory concentration (IC50) of the compound preparation for inhibiting head and neck cancer cells.

[0028] Figure 2 The statistical results of head and neck cancer cell proliferation detection after treatment in the control group and the compound preparation group are shown. *P<0.05 compared with the control group.

[0029] Figure 3 Representative images and statistical results of apoptosis in head and neck cancer cells after treatment with the control group and the combined treatment group were obtained by flow cytometry. *P<0.05 compared with the control group.

[0030] Figure 4 The results show the effect of the compound preparation on inhibiting the proliferation of head and neck cancer cells. *P<0.05 compared with the control group or the extract using ordinary water as a solvent.

[0031] Figure 5 The compound formulation was used to enhance the effect of cisplatin in killing head and neck cancer cells. Detailed Implementation

[0032] To make the objectives, technical solutions, and advantages of this application clearer, the technical solutions in the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some, not all, of the embodiments of this application.

[0033] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains.

[0034] Example 1

[0035] This embodiment provides a pharmaceutical composition for killing head and neck cancer cells, comprising deuterated water, selenium-containing extract, cassia seed extract, and honeysuckle extract. In this embodiment, the four core components are not simply a physical mixture, but an organic whole formed based on specific functional localization. The deuterated water, in particular, does not merely act as an inert solvent or conventional carrier for dissolving other components, but rather participates in the anti-tumor process as a bioactive functional medium. Through its unique hydrogen bond network structure and low deuterium abundance, the deuterated water can alter the intracellular metabolic microenvironment, while simultaneously promoting the transmembrane transport and intracellular retention of the selenium-containing extract and the active ingredients of the traditional Chinese medicine, thus forming a synergistic system of "carrier-enhanced penetration + multi-target intervention" with the latter three components.

[0036] In one specific embodiment, the pharmaceutical composition comprises the following components in parts by weight: 400-600 parts of deuterated water; 1-3 parts of selenium-containing extract; 0.5-2 parts of cassia seed extract; and 0.5-2 parts of honeysuckle extract. Within this ratio range, the solvent effect of the deuterated water and the pharmacodynamic effects of each active ingredient can achieve a dynamic balance. For example, when the amount of deuterated water is less than 400 parts, it may not be possible to sufficiently construct a deuterated microenvironment conducive to the penetration of active ingredients, and the stability of the formulation may decrease; while when the amount exceeds 600 parts, although safety is not a concern, the concentration of the active ingredient per unit volume is excessively diluted, which may lead to a weakening of the synergistic anticancer effect. Similarly, the ratio of selenium-containing extract, cassia seed extract, and honeysuckle extract should also be maintained within the above range to avoid the toxicity risk or antagonistic effect caused by excessive amounts of a single component. Based on this, this embodiment further preferably comprises the following components in parts by weight: 500 parts of deuterated water; 2 parts of selenium-containing extract; 1 part of cassia seed extract; and 1 part of honeysuckle extract. This optimal ratio is the golden ratio obtained through extensive experimental screening and verification. At this ratio, the compound preparation has the lowest half-maximal inhibitory concentration (IC50) against head and neck cancer cells, and the synergistic interaction between the components is the most significant, achieving the best balance between efficacy and safety.

[0037] The specific preparation process can be carried out according to the following steps: First, dissolve the high-methylselenocysteine ​​selenium-enriched malt extract in deuterium-free water and stir until fully dispersed; then add cassia seed extract and honeysuckle extract, and sonicate for about 30 minutes to promote the uniform fusion and intermolecular interaction of the components in the deuterium-free water medium; finally, filter and sterilize to obtain the final product. It should be understood that the above preparation steps are only illustrative examples, and other conventional mixing, homogenization, or dissolution processes can also be used to achieve the compatibility of the components without departing from the concept of this application.

[0038] To ensure the biological activity of the pharmaceutical composition, this embodiment strictly limits the physicochemical properties of the core raw materials. Specifically, the deuterium concentration of the low-deuterium water is less than or equal to 120 ppm; the selenium-containing extract is a high-methylselenocysteine ​​selenium-enriched malt extract. Deuterium concentration is a key threshold determining whether low-deuterium water can inhibit tumor cell mitosis. Only when the deuterium concentration is reduced to 120 ppm or below can it effectively interfere with the deuteration metabolic reaction in cancer cells and block their abnormal proliferation cycle. If ordinary water or weakly low-deuterium water with a deuterium concentration higher than this threshold is used, it is difficult to produce the expected metabolic intervention effect. More preferably, the deuterium concentration of the low-deuterium water is less than or equal to 100 ppm; the high-methylselenocysteine ​​selenium-enriched malt extract has a selenium content greater than or equal to 1000 ppm and a methylselenocysteine ​​content greater than or equal to 800 ppm. Further reducing the deuterium concentration to below 100 ppm can enhance its cell cycle arrest effect. Meanwhile, high-methylselenocysteine ​​was chosen as the selenium source because, compared to inorganic selenium such as sodium selenite or other organic selenium forms, methylselenocysteine ​​has higher bioavailability and tumor targeting. It can be specifically converted into active selenium metabolites within cancer cells, inducing mitochondrial apoptosis pathways, while exhibiting significantly lower toxicity to normal cells. Specifying the lower limits for selenium content and methylselenocysteine ​​content ensures an adequate supply of active selenium in each batch of formulation, guaranteeing consistency in clinical efficacy.

[0039] Regarding the components of the herbal extracts, this embodiment explicitly states that the cassia seed extract contains anthraquinones; and the honeysuckle extract contains chlorogenic acid. These two types of components are the material basis for the synergistic anti-inflammatory and anti-tumor effects of cassia seed and honeysuckle. To ensure the enrichment of active ingredients, the mass percentage of anthraquinones in the cassia seed extract is greater than or equal to 15%; the mass percentage of chlorogenic acid in the honeysuckle extract is greater than or equal to 20%. The cassia seed extract is obtained by extracting cassia seed with an ethanol-water solution; the honeysuckle extract is obtained by extracting honeysuckle with water. Specifically, the extraction process can employ 70% ethanol reflux extraction of cassia seed, and water decoction combined with macroporous resin purification of honeysuckle. This differentiated solvent system is designed based on the polarity characteristics of the two types of components: the ethanol-water solution can efficiently enrich anthraquinones with moderate polarity, while water extraction is more suitable for retaining water-soluble active substances such as chlorogenic acid and removing lipid-soluble impurities. Only when the content of the active ingredient reaches the lower limit mentioned above can a sufficiently strong multi-target synergistic network be formed in the compound with deuterium water and selenium source; otherwise, the overall efficacy may be greatly reduced due to insufficient active substances.

[0040] Regarding dosage form selection, the drug composition is available in oral liquid or lyophilized powder for injection. The oral liquid formulation facilitates long-term oral administration, making it particularly suitable for adjuvant therapy and nutritional support during radiotherapy and chemotherapy. The lyophilized powder for injection utilizes freeze-drying technology to improve the stability of the active ingredients, especially selenium compounds and traditional Chinese medicine extracts, making it suitable for intravenous administration scenarios requiring precise dosage control. In actual production, appropriate pharmaceutical excipients, such as flavoring agents, preservatives, or excipients, can be added according to clinical needs to meet the preparation requirements of different dosage forms.

[0041] To verify the synergistic necessity of the components in the pharmaceutical composition provided in this embodiment, the applicant set up multiple comparative groups to compare the in vitro anticancer effects, and the results are as follows: Figure 4 As shown in the figure, experimental data show that the composite formulation prepared using ordinary water instead of deuterium-rich water as a solvent has a significantly lower inhibitory effect on the proliferation of head and neck cancer cells than the full-combination formulation using deuterium-rich water as a carrier in this embodiment. This directly proves that deuterium-rich water is not a dispensable inert solvent in this application, but an indispensable active synergistic component. Furthermore, whether using selenium-containing extracts, cassia seed extracts, or honeysuckle extracts individually, or combining them in pairs, their anticancer effects are significantly weaker than the full-combination formulation using all four. This result quantitatively demonstrates the technical fact that "all four are indispensable," indicating that the pharmaceutical composition of this application produces an unexpected synergistic effect, rather than a simple additive effect of the individual components. This synergistic effect is the core difference between this application and the single-component application or simple physical mixing schemes in the prior art, and it also lays the material basis for the excellent antitumor activity demonstrated in subsequent embodiments.

[0042] Example 2

[0043] This embodiment, based on the pharmaceutical composition provided in Example 1, further verifies its application value in the biopharmaceutical field. Specifically, this application provides the application of the pharmaceutical composition described in Example 1 in the preparation of a drug for killing head and neck cancer cells. This application establishes the pharmaceutical use of this composition as a novel antitumor agent, the core of which lies in utilizing a synergistic system of a low-deuterium water carrier and multi-target active ingredients to achieve highly efficient killing of head and neck malignant tumor cells. To fully support the above use and clarify specific clinical application scenarios, in this embodiment, head and neck cancer cells include nasopharyngeal cancer cells, laryngeal cancer cells, or oral cancer cells; and the pharmaceutical composition is configured as a chemosensitizer for use in combination with cisplatin. This means that the pharmaceutical composition can not only be used as an independent antitumor drug, but also as an adjuvant to existing platinum-based chemotherapy regimens, reducing toxic side effects and overcoming drug resistance by lowering the effective dose threshold of chemotherapeutic drugs.

[0044] To verify the direct killing efficacy of this drug composition against head and neck cancer cells, this embodiment uses the human head and neck squamous cell carcinoma line FaDu as a model for a systematic in vitro pharmacodynamic evaluation. Figure 1 As shown, the effect of different volume concentrations (0, 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80 µl) of the compound formulation on FaDu cell viability was detected using the MTT assay, and dose-response curves were plotted. The experimental results showed that the half-maximal inhibitory concentration (IC50) of the drug composition was 56.29 μl. This data establishes the effective concentration window for the formulation to exert a significant anti-cancer effect in vitro, indicating that 50% growth inhibition of cancer cell populations can be achieved near this concentration, providing an important in vitro reference benchmark for determining the subsequent clinical dosage.

[0045] Further mechanistic studies confirmed that the inhibitory effect of this drug composition on FaDu cells stems from specific proliferation arrest and apoptosis induction, rather than non-specific cytotoxicity. Figure 2 As shown, after treating FaDu cells with 60 μl of the compound preparation, the cell proliferation level (OD value) in the treated group was significantly lower than that in the PBS control group, and the difference was statistically significant (P < 0.05). This indicates that the drug composition can effectively block the cell cycle of cancer cells. Meanwhile, as... Figure 3 Flow cytometry results showed that the apoptosis rate of FaDu cells significantly increased after treatment with the compound formulation. In the flow cytometry scatter plot, the sum of the proportions of cells in quadrants Q2 and Q3, representing early and late apoptosis, was significantly increased compared to the PBS control group. Quantitative statistics showed that the percentage of apoptotic cells was close to 60%, while the control group only had about 30%. These data collectively reveal the biological mechanism by which this drug composition eliminates cancer cells through the induction of programmed cell death, validating its effectiveness as a drug for killing head and neck cancer cells.

[0046] Regarding combination therapy strategies, this embodiment focuses on the functional role of the drug composition as a chemotherapy sensitizer. Cisplatin is a first-line chemotherapy drug for the clinical treatment of head and neck cancer, but its use is often limited due to dose-dependent toxicity and acquired resistance. For example... Figure 5 As shown, the IC50 value of cisplatin alone in FaDu cells was 5242 nM; however, when cisplatin was used in combination with the drug composition described in this example, the IC50 value of cisplatin significantly decreased to 1618 nM. Calculations showed that the combination therapy increased cisplatin sensitivity by approximately 3.2 times. This quantified sensitization effect has significant clinical translational implications, meaning that while maintaining equivalent antitumor efficacy, the clinical dosage of cisplatin can be significantly reduced, thereby effectively alleviating adverse reactions such as nephrotoxicity, neurotoxicity, and severe oral mucositis caused by cisplatin. The microscopic mechanism of this sensitization effect may be related to multiple factors, including the improvement of the tumor microenvironment by low-deuterium water, the promotion of cisplatin transmembrane transport, and the reversal of multidrug resistance protein expression by traditional Chinese medicine extracts.

[0047] In practice, the combination therapy with cisplatin can be flexibly adjusted according to actual clinical needs. For example, simultaneous administration can be used, where the drug composition and cisplatin are administered to the patient within the same treatment cycle to enhance the killing efficiency of cisplatin by synchronizing the cell cycle with the drug composition. Sequential administration can also be used, such as pre-treating the patient with the drug composition for a certain period of time, and then administering cisplatin after the tumor microenvironment has improved or the drug resistance pathway has been inhibited, to maximize the sensitization effect. It should be understood that regardless of the administration sequence, any treatment regimen that includes the combination therapy of the drug composition and cisplatin of this application falls within the scope of protection of this application. Furthermore, although this embodiment mainly uses FaDu cells (derived from hypopharyngeal / laryngeal cancer regions) as an example for verification, based on the high similarity in pathophysiological characteristics of head and neck squamous cell carcinoma and the multi-target synergistic mechanism of action of the drug composition of this application, those skilled in the art can reasonably expect that the drug composition will also have significant killing and sensitization effects on other types of head and neck cancer cells such as nasopharyngeal cancer cells and oral cancer cells. Therefore, the scope of this application should not be construed as limited to the cell lines specifically tested in the embodiments, but rather covers all types of head and neck cancer cells and their related indications as defined in the claims.

[0048] The above description is merely a specific embodiment of this application, but the scope of protection of this application is not limited thereto. Any person skilled in the art, within the technical scope disclosed in this application, based on the technical concept of low-deuterium water carrier promoting permeation and multi-target active ingredients synergistically killing head and neck cancer cells, can easily conceive of equivalent changes or substitutions to the component ratios, raw material sources, extraction process parameters, selection of formulation excipients, or the timing of combined administration. Such changes or substitutions, as long as they do not depart from the core inventive concept of this application and can achieve the same or similar technical effects, should be included within the scope of protection of this application. Therefore, the scope of protection of this application should be determined by the scope of the claims.

Claims

1. A pharmaceutical composition for killing head and neck cancer cells, characterized in that, The pharmaceutical composition comprises deuterium-free water, selenium-containing extract, cassia seed extract, and honeysuckle extract.

2. The pharmaceutical composition according to claim 1, characterized in that, The pharmaceutical composition comprises the following components in parts by weight: The deuterium-rich water is 400-600 parts; 1-3 parts of the selenium-containing extract; 0.5-2 parts of the cassia seed extract; The honeysuckle extract is 0.5-2 parts.

3. The pharmaceutical composition according to claim 2, characterized in that, The pharmaceutical composition comprises the following components in parts by weight: 500 portions of the deuterium-rich water; Two portions of the selenium-containing extract; One part of the cassia seed extract; One part of the honeysuckle extract.

4. The pharmaceutical composition according to claim 1, characterized in that, The deuterium concentration of the low-deuterium water is less than or equal to 120 ppm; The selenium-containing extract is a selenium-enriched malt extract containing high-methylselenocysteine.

5. The pharmaceutical composition according to claim 4, characterized in that, The deuterium concentration of the low-deuterium water is less than or equal to 100 ppm; The selenium-enriched malt extract containing high methylselenocysteine ​​has a selenium content greater than or equal to 1000 ppm and a methylselenocysteine ​​content greater than or equal to 800 ppm.

6. The pharmaceutical composition according to claim 1, characterized in that, The cassia seed extract contains anthraquinone components; The honeysuckle extract contains chlorogenic acid.

7. The pharmaceutical composition according to claim 6, characterized in that, The mass percentage of the anthraquinone components in the cassia seed extract is greater than or equal to 15%; The honeysuckle extract contains chlorogenic acid at a mass percentage greater than or equal to 20%; The cassia seed extract was obtained by extracting cassia seeds with an ethanol-water solution; The honeysuckle extract is obtained by water extraction of honeysuckle.

8. The pharmaceutical composition according to claim 1, characterized in that, The dosage form of the pharmaceutical composition is an oral liquid or a lyophilized powder for injection.

9. Use of the pharmaceutical composition according to any one of claims 1 to 8 in the preparation of a medicament for killing head and neck cancer cells.

10. The application according to claim 9, characterized in that, The head and neck cancer cells include nasopharyngeal cancer cells, laryngeal cancer cells, or oral cancer cells; The drug is a chemosensitizer used in combination with cisplatin.

Images